Vaccine Development and T Cell Therapy Team

Research interests

The Team is focused on the development and optimization of personalized vaccines targeting glioma-specific and glioma-associated antigens and the identification of glioma-specific T cell receptors.

Main projects

  • IDH1R132H-specific immunotherapy
  • H3.3.K27M-specific immunotherapy
  • Mutanome-based vaccine development (BrainTuNE)
  • Translational research programs of the clinical trials NOA-16 and AMPLIFY-NEOVAC
  • Combinatorial immunotherapies
  • Major histocompatibility complex II in gliomas

© dkfz.de

Team members

  • Lukas Bunse
  • Theresa Bunse
  • Katrin Deumelandt
  • Mirco Friedrich
  • Edward Green
  • Simone Karcher-Bausch
  • Anna von Landenberg
  • Kevin Lu
  • Iris Mildenberger
  • Katharina Ochs
  • Khwab Sanghvi

Publications

Immuntherapien bei Gliomen

Ochs K, Bunse L, Mildenberger I, Wick W, Platten M

Onkologe. 2017 doi: 10.1007/s00761-017-0258-y

K27M-mutant histone-3 as a novel target for glioma immunotherapy.

Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M.

Oncoimmunology. 2017 May 12;6(7):e1328340. doi: 10.1080/2162402X.2017.1328340. eCollection 2017.

Concepts in glioma immunotherapy.

Platten M, Bunse L, Wick W, Bunse T.

Cancer ImmunolImmunother. 2016 Oct;65(10):1269-75. doi: 10.1007/s00262-016-1874-x. Epub 2016 Jul 26. Review.

Cancer immunotherapy: exploiting neoepitopes.

Platten M, Offringa R.

Cell Res. 2015 Aug;25(8):887-8. doi: 10.1038/cr.2015.66. Epub 2015 Jun 2.

Mutant IDH1: An immunotherapeutic target in tumors.

Schumacher T, Bunse L, Wick W, Platten M.

Oncoimmunology. 2015 Jan 7;3(12):e974392. eCollection 2014 Dec.

Proximity ligation assay evaluates IDH1R132H presentation in gliomas.

Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M.

J Clin Invest. 2015 Feb;125(2):593-606. doi: 10.1172/JCI77780. Epub 2015 Jan 2.

A vaccine targeting mutant IDH1 induces antitumour immunity.

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M.

Nature. 2014 Aug 21;512(7514):324-7. doi: 10.1038/nature13387. Epub 2014 Jun 25.

nach oben